Moreover, in the era of PM in oncology, pharmacogenomics nowadays provides essential information for therapy outcome such as in cases of Kirsten rat sarcoma oncogene or KRAS (cetuximab/panitumumab), v-raf murine sarcoma viral oncogene homolog B or BRAF (vemurafenib), epidermal growth factor receptor or EGFR (gefitinib, erlotinib), tyrosine-protein kinase KIT CD117 (cluster of differentiation 117) or c-KIT (imatinib) and microtubule-associated protein-like 4-anaplastic aymphoma Kinase or EML4-ALK (crizotinib) [32,33,34,35,36]. The gene discussed is BRAF; the disease is sarcoma.